CEL-SCI (CVM) announced that a Breakthrough Medicine Designation application has been filed with the Saudi Food and Drug Authority for Multikine in Saudi Arabia. The application was submitted by a premier Saudi pharma company with which CEL-SCI has signed a memorandum of understanding for the commercialization of Multikine.The response time to the application is approximately 60 days. If granted, the designation would immediately make Multikine available for patient access and reimbursement in Saudi Arabia.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVM: